Jazz Pharmaceuticals: The Concept Bet, at a Whole New Level

The press around the size of Jazz Pharmaceuticals' $250 million private financing has obscured the whole point: the company and the financing represent a fundamentally different business model for biopharmaceutical investing and companies: betting on product concepts--not products and not technology.

If you only read the press—of which there was plenty--about Jazz Pharmaceuticals Inc. 's $250 million private financing, [See Deal] all you'd probably have learned is that it was the biggest series B round ever and that the deal represented the debut of Kohlberg Kravis Roberts & Co.—best known for mega-LBOs--into the very unleveraged world of biopharmaceuticals.

And you would have missed the whole point. Jazz represents a fundamentally different business model for biopharmaceutical investing and companies:...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Business Strategy

More from In Vivo